Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

A-H Premium Weekly: Shanghai Pharma, China Eastern Air, Huaneng Power, Shenzhen Hepalink

A-H Premium Weekly: Real Estate at 52 Week High

A-H Premium Weekly: Healthcare Led Premium Decline

A/H Premium Weekly: BYD, Xinjiang Gold Wind, Ganfeng Lithium

A/H Premium Weekly: 15 Stocks at 52 Week High

A/H Premium Weekly: Xinjiang Goldwind, Great Wall Motor, First Tractor

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

China Consumer discretionary / Quantitative Analysis

<ul>
<li>We analyse the changes of A/H premium on 136 stocks over the last week.</li>
<li>Average A/H premium was 4.7ppt lower last week, led by consumer discretionary, material and healthcare. </li>
<li>37 stocks reached 52 week high last week but most have retreated since, representing arb opportunities in volatile market. </li>
</ul>


We analyse the changes of A/H premium on 136 stocks over the last week.
Average A/H premium was 4.7ppt lower last week, led by consumer discretionary, material and healthcare. 
37 stocks reached 52 week high last week but most have retreated since, representing arb opportunities in volatile market. 


Shanghai Pharmaceuticals Holding (2607 HK)

China Railway Construction Corp (1186 HK)

Chongqing Iron & Steel Co Ltd H (1053 HK)

Zhengzhou Coal Mining Machinery Group Co (564 HK)

Beijing Chunlizhengda Medical Instruments (1858 HK)

Beijing Chunlizhengda Medical Instruments

Shanghai Fosun Pharmaceutical (Group) (2196 HK)

Xinjiang Goldwind Science & Technology (2208 HK)

Shanghai Fudan Microelectronics H (1385 HK)

China Merchants Securities Co Ltd (H) (6099 HK)

Shanghai Dazhong Public Utilities - H (1635 HK)

Shenzhen HepaLink Pharmaceutical (H) (9989 HK)

A/H Premium Weekly: Arb Opportunities Last Week